Showing results (221-230 of 479) with videos related to

Sort By:
Pageof 48
Pharmaceutical Research|April 28, 2011
How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurementsAndreas Schädlich, Cornelia Rose, Judith Kuntsche, et al.
Nature Communications|April 14, 2019
Electroluminescence from multi-particle exciton complexes in transition metal dichalcogenide semiconductorsMatthias Paur, Aday J Molina-Mendoza, Rudolf Bratschitsch, et al.
International Journal of Molecular Sciences|March 29, 2023
Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for TherapyArne Rotermund, Sarah Brandt, Martin S Staege, et al.
European Journal of Medicinal Chemistry|December 4, 2018
New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agentsFlorian Schmitt, Madeleine Gold, Matthias Rothemund, et al.
European Journal of Medicinal Chemistry|April 27, 2016
Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumorsKatharina Mahal, Bernhard Biersack, Sebastian Schruefer, et al.
Current Medicinal Chemistry|July 23, 2003
Biomolecules linked to transition metal complexes--new chances for chemotherapyReinhard Paschke, Christian Paetz, Thomas Mueller, et al.
Histochemistry and Cell Biology|June 10, 2010
Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivityThomas Mueller, Lutz Peter Mueller, Hans-Juergen Holzhausen, et al.
Cell Cycle (Georgetown, Tex.)|February 18, 2009
The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiationTemuujin Dansranjavin, Susanne Krehl, Thomas Mueller, et al.
Macromolecular Bioscience|September 23, 2016
Passive Tumor Targeting of Polymer Therapeutics: In Vivo Imaging of Both the Polymer Carrier and the Enzymatically Cleavable Drug ModelRobert Pola, Anne-Kathrin Heinrich, Thomas Mueller, et al.
Pageof 48